Phase 3 study evaluating AMG 757 Tarlatamab for patients with Small Cell Lung Cancer

Brief description of study

This study is for patients with small cell lung cancer (SCLC). They want to see if a new treatment called tarlatamab (an immunotherapy that might fight against the cancer cells and make patients feel better) with standard of care (SOC) therapy is better than prior platinum-containing therapy. The study has different parts, like checking if patients can join at the beginning, doing tests to make sure they're eligible, and then giving them the treatment. If things go well, they can stay on the treatment even after their cancer gets worse. They also have some check-up visits to make sure everyone is okay. This whole study will last for a few years and might take about 9 to 12 months for each patient who joins. The study team will be following a lot of people to learn more about the treatments.

Clinical Study Identifier: s23-00358

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.